TCL Archive In Brief: Gramm-Rudman-Hollings Could Slash NCI Budget By $650 Million; Holleb Retires From ‘Ca’ July 27, 1990
TCL Archive FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says. January 14, 2005
TCL Archive Childhood Cancer Survivors Do Not Have an Increased Risk Of Passing On Birth Defects December 30, 2011
TCL Archive FDA Approved More Than 50 New Indications For Cancer In 32 Months, Analysis Finds February 19, 2010
TCL Archive Also in this 8-page Issue: Safety Warnings Are Added to Labels for Epo and Avastin. January 21, 2005
